Researchers at Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and University of Michigan have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker.
Scientists at Jisikai (Suzhou) Pharmaceutical Co. Ltd. and Yaopharma Co. Ltd. have disclosed polycyclic N-heterocyclic ketone compounds reported to be useful for the treatment of HIV infection.
Onkure Inc. has described phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and scoliosis (CLOVES syndrome), and PIK3CA-related overgrowth spectrum (PROS).
Sironax Ltd. has divulged nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) activators reported to be useful for the treatment of cancer, neurodegeneration, inflammation, and mitochondrial, metabolic, cardiovascular, muscle and renal disorders, among others.
Ildong Pharmaceutical Co. Ltd. has identified novel tetraheterocycle compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Shandong Ruzhi Biomedical Technology Co. Ltd. has synthesized compounds reported to be useful for the treatment of neurodegeneration, cardiovascular disorders and cerebrovascular disorders.
Erasmus University Rotterdam has disclosed compounds targeting fibroblast activation protein-α (FAPα) reported to be useful for the diagnosis and treatment of cancer.
The Hatch-Waxman Act provides a safe harbor that allows importation of an FDA-regulated article that would otherwise be deemed a case of patent infringement so long as the importation is for purposes reasonably related to obtaining regulatory approval. Edwards Lifesciences Corp. sued Meril Life Sciences Pvt Ltd. for importation of heart valves in a manner that Edwards argued was infringement under Hatch-Waxman, but while the Federal Circuit ruled 2-1 against Edwards, the dissenting opinion recommended an appeal to a full 12-judge panel that could reverse this outcome.
The University of Florida Health Proton Therapy Institute’s director of Physics, Perry Johnson, has filed for protection of a method for patient posture and alignment using mixed reality (MixR) visualization.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described Toll-like receptor 7 (TLR7) and/or TLR8 agonists and their immunostimulatory antibody conjugates (ISACs) consisting of antibodies covalently linked to TLR7 and/or TLR8 agonists through cleavable or uncleavable linkers.